Glenmark readies for launch of Napo's crofelemer
This article was originally published in Scrip
Glenmark Pharmaceuticals is preparing for the launch of Napo Pharmaceuticals' novel anti-secretory gastrointestinal agent, crofelemer, in 140 emerging and developing world countries, following positive Phase III results for the product for the treatment of chronic diarrhoea in people living with HIV/AIDS.
You may also be interested in...
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.